EU/3/13/1102: Orphan designation for the treatment of high-altitude pulmonary oedema
Cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr-Cys
Table of contents
Overview
On 8 February 2013, orphan designation (EU/3/13/1102) was granted by the European Commission to Apeptico Forschung und Entwicklung GmbH, Austria, for Cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr-Cys for the treatment of high-altitude pulmonary oedema.
Key facts
Active substance |
Cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr-Cys
|
Intended use |
Treatment of high-altitude pulmonary oedema
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/13/1102
|
Date of designation |
08/02/2013
|
Sponsor |
Apeptico Forschung und Entwicklung GmbH
MariahilferStraße 136, Top 1.15 1150 Vienna Austria Tel. +43 664 1432 919 Fax +43 125 3303 37795 E-mail: b.fischer@apeptico.com |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: